Preclinical Imaging Market worth $4.39 billion by 2030
The report "Preclinical Imaging Market by Product (Optical Imaging (Bioluminescence), Nuclear Imaging (PET, SPECT), MRI, Reagents (Luciferins, Infrared Dyes), Software), Application (Onco, Cardio), End User (Pharma, Biotech, Academic, CRO) - Global Forecast to 2030", is projected to reach USD 4.39 billion by 2030 from USD 3.53 billion in 2025, at a CAGR of 4.5%.
Browse 1000 market data Tables and 50 Figures spread through 600 Pages and in-depth TOC on "Preclinical Imaging Market by Product (Optical Imaging (Bioluminescence), Nuclear Imaging (PET, SPECT), MRI, Reagents (Luciferins, Infrared Dyes), Software), Application (Onco, Cardio), End User (Pharma, Biotech, Academic, CRO) - Global Forecast to 2030"
View detailed Table of Content here - https://www.marketsandmarkets.com/Market-Reports/pre-clinical-molecular-imaging-market-841.html
The growth in the preclinical imaging market is driven by increasing funding to support preclinical research, the development of low-cost & affordable preclinical imaging systems, and the growing market demand for new drug development and non-invasive small-animal imaging techniques.
The optical imaging reagents segment is the largest product type of the preclinical reagents market in 2024.
Based on reagents, the preclinical imaging market is segmented into optical imaging reagents, nuclear imaging reagents, MRI contrast agents, ultrasound contrast agents, and CT contrast agents. Among these, the optical imaging reagents segment accounted for the largest share of the preclinical imaging market in 2024. The large market share of the optical imaging reagents segment is attributed to the high penetration of optical imaging modalities in preclinical research studies.
The oncology segment is the largest application segment of the preclinical imaging market in 2024.
Based on application, the preclinical imaging market is segmented into oncology, cardiology, neurology, infectious diseases, immunology & inflammation, and other applications. In 2024, the oncology segment accounted for the largest share of the market. This can be due to the fact that oncology greatly benefits from advancements in molecular imaging, allowing researchers to target specific biomarkers associated with cancer cells. This provides valuable insights into tumor biology and drug targeting.
By end user, pharmaceutical & biotechnology companies are the largest end-user segment in the preclinical imaging market in 2024.
Based on end user, the preclinical imaging market is segmented into pharmaceutical & biotechnology companies, academic & research centers, contract research organizations (CROs), and other end users. In 2024, the pharmaceutical & biotechnology companies segment accounted for the largest share of the market. The volume of research & development work conducted by these companies has increased significantly, accompanied by a rise in investment for these activities. The ongoing need for advanced drugs will continue to drive demand for research and development efforts. Biotechnology companies utilize this technology extensively due to its wide range of applications.
North America dominated the global preclinical imaging market in 2024.
The preclinical imaging market is segmented into five major regional segments, namely, North America, Europe, Asia Pacific, Latin America, and the Middle East and Africa. North America is anticipated to dominate the preclinical imaging market due to its developed infrastructure, numerous preclinical projects, and higher adoption rates of advanced technological devices in the region.
Key Players
Prominent players in the preclinical imaging market include MR Solutions (UK), Mediso Ltd. (UK), Sofie (US), Fujifilm Visual Sonics (Canada), MILABS B.V. (Netherlands), Aspect Imaging Limited (US), Li-Cor Biosciences (US), ICONEUS (Paris), Advanced Molecular Vision (UK), Viewworks (Korea), Kub Technologies (US), Medikor (US), Trifoil Imaging (US), IVIM Technology Corp. (South Korea), Cubresa, Inc. (Canada), Berthold Technologies GmbH & Co. KG (Germany), Miltenyi Biotech GmbH (Germany), AI4R (France), Bruker Corporation (US), and Revvity, Inc. (US).
About MarketsandMarkets™
MarketsandMarkets™ has been recognized as one of America's Best Management Consulting Firms by Forbes, as per their recent report.
MarketsandMarkets™ is a blue ocean alternative in growth consulting and program management, leveraging a man-machine offering to drive supernormal growth for progressive organizations in the B2B space. With the widest lens on emerging technologies, we are proficient in co-creating supernormal growth for clients across the globe.
Today, 80% of Fortune 2000 companies rely on MarketsandMarkets, and 90 of the top 100 companies in each sector trust us to accelerate their revenue growth. With a global clientele of over 13,000 organizations, we help businesses thrive in a disruptive ecosystem.
The B2B economy is witnessing the emergence of $25 trillion in new revenue streams that are replacing existing ones within this decade. We work with clients on growth programs, helping them monetize this $25 trillion opportunity through our service lines – TAM Expansion, Go-to-Market (GTM) Strategy to Execution, Market Share Gain, Account Enablement, and Thought Leadership Marketing.
Built on the 'GIVE Growth' principle, we collaborate with several Forbes Global 2000 B2B companies to keep them future-ready. Our insights and strategies are powered by industry experts, cutting-edge AI, and our Market Intelligence Cloud, KnowledgeStore™, which integrates research and provides ecosystem-wide visibility into revenue shifts.
To find out more, visit www.MarketsandMarkets™.com or follow us on Twitter , LinkedIn and Facebook .
Contact:
Mr. Rohan Salgarkar
MarketsandMarkets™ INC.
1615 South Congress Ave.
Suite 103, Delray Beach, FL 33445
USA: +1-888-600-6441
Email: sales@marketsandmarkets.com
Visit Our Website: https://www.marketsandmarkets.com/
- Triangulate with your Own Data
- Get Data as per your Format and Definition
- Gain a Deeper Dive on a Specific Application, Geography, Customer or Competitor
- Any level of Personalization
- What are the Known and Unknown Adjacencies Impacting the Preclinical Imaging Market
- What will your New Revenue Sources be?
- Who will be your Top Customer; what will make them switch?
- Defend your Market Share or Win Competitors
- Get a Scorecard for Target Partners
